| Supplementation of glutamine and omega-3 polyunsaturated fatty acids as a novel therapeutic intervention targeting metabolic dysfunction and exercise intolerance in patients with heart failure. | |
| | |
MedLine Citation:
|
PMID: 22082326 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
With its increasing prevalence throughout the world, heart failure continues to be associated with high morbidity and mortality. Patients with heart failure develop progressive metabolic abnormalities, inflammation, and atrophy in the myocardium and skeletal muscle. Improvement in functional capacity as defined by exercise tolerance is essential for better quality of life and potentially survival of these patients. Therapeutic management options aimed at improving peripheral organ function are limited. Nutritional approaches with dietary supplementation in addition to current therapies are particularly appealing as they are novel and mechanistically different. In this article, we review the role of glutamine and omega-3 polyunsaturated fatty acids on metabolism and functional capacity in heart failure. These two compounds are of particular interest due to their synergistic role on oxidative metabolism, lipolysis and inflammation. |
| | |
Authors:
|
Khurram Shahzad; Aalap Chokshi; P Christian Schulze |
Related Documents
:
|
21631836 - Resistance exercises for health promotion in coronary patients: evidence of benefits an... 2540146 - Effect of exercise duration on density and coupling of beta-adrenergic receptors on hum... 7753426 - Influence of beta-blockade with metoprolol on symptoms and functional capacity of patie... 10526196 - Further study on the specificity and incidence of neutralizing antibodies to interferon... 2456556 - Nonlinear relationship between pacing and evoked qt intervals. 9467576 - Sodium regulating hormones at high altitude: basal and post-exercise levels. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Review |
Journal Detail:
|
Title: Current clinical pharmacology Volume: 6 ISSN: 2212-3938 ISO Abbreviation: Curr Clin Pharmacol Publication Date: 2011 Nov |
Date Detail:
|
Created Date: 2011-12-13 Completed Date: 2012-04-09 Revised Date: 2012-05-24 |
Medline Journal Info:
|
Nlm Unique ID: 101273158 Medline TA: Curr Clin Pharmacol Country: United Arab Emirates |
Other Details:
|
Languages: eng Pagination: 288-94 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Division of Cardiology, New York-Presbyterian Hospital/Columbia University MedicalCenter, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Dietary Supplements Drug Synergism Exercise Tolerance Fatty Acids, Omega-3 / pharmacology*, therapeutic use Glutamine / pharmacology*, therapeutic use Heart Failure / drug therapy*, physiopathology Humans Inflammation / drug therapy, physiopathology Lipolysis / drug effects Metabolic Diseases / drug therapy, etiology Quality of Life |
| Grant Support | |
ID/Acronym/Agency:
|
HL095742-02/HL/NHLBI NIH HHS; HL101272-01/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Fatty Acids, Omega-3; 56-85-9/Glutamine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Unexpected high levels of vorinostat when combined with vinorelbine in patients with advanced cancer...
Next Document: Drug-induced anemia and other red cell disorders: a guide in the age of polypharmacy.